Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 12/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650402 | 0.85 | CDK4 (0.34) | CDK4CDK6CCND1CCND3CDK2 | |
| SCHEMBL22650827 | 0.83 | CDK4 (0.39) | CDK4CDK6CCND1CCND3CDK2 | |
| SCHEMBL29827502 | 0.82 | CDK4 (0.51) | CDK4CDK6CCND1CCND3EGFR | |
| SCHEMBL15252434 | 0.82 | CDK4 (0.51) | CDK4CDK6CCND1CCND3EGFR | |
| SCHEMBL29491131 | 0.79 | MAPK14 (0.40) | CDK2CDK1 | |
| SCHEMBL22650600 | 0.79 | MAPK14 (0.40) | CDK2CDK1 | |
| SCHEMBL30039841 | 0.78 | CDK2 (0.38) | CDK4CDK6CCND1CCND3CDK2 | |
| SCHEMBL30040812 | 0.76 | CDK4 (0.36) | CDK4CDK6CCND1CCND3CDK2 | |
| SCHEMBL26066673 | 0.75 | CDK4 (0.40) | CDK4CDK6CCND1CCND3EGFR | |
| SCHEMBL30040929 | 0.75 | CDK2 (0.35) | CDK4CCND1CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | CDK4 10/4885CDK6 3/4885CCND1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.